
Nano-Pharmacokinetics and Theranostics
Advancing Cancer Therapy
- 1st Edition - July 28, 2021
- Imprint: Academic Press
- Editors: Nanasaheb D. Thorat, Nitesh Kumar
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 0 5 0 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 8 2 - 0
Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspecti… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteNano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspectives of nano-pharmacokinetics using cancer as a model disease. Nano-pharmacokinetics is emerging as an important sub discipline of nanoscience and medical sciences because of the increasing safety issues of nanosystems on living organisms. This book reports the dynamics of nanosystems in living organisms for better understanding of nanotoxicity, pharmacology, biochemistry, physiology and medicine perspectives. It further examines current progress of state-of-the art pharmacokinetics mechanisms, which will be of great help to develop more clinical-oriented nanosystems with a wide safety margin. The book is divided into three sections: the first section focuses on the concept of pharmacokinetics with state-of-the-art Nano-Pharmacokinetics (NPK). The second section looks at the engineering of nanoparticles and pharmacokinetics clinical development. The final section focuses on Nano-Pharmacokinetics and Theranostics, elaborating the basic question of how pharmacokinetics of nanomaterials relate to their end applications such as cancer therapy. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy will be useful to researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians.
- Includes contributions from highly qualified scientists, regulatory entities, enterprises and medical practitioners to explain the long and inherently multidisciplinary pathway of nano-pharmacokinetics
- Describes assessment methods of nano-pharmacokinetics
- Examines the interface between nanomedicine and pharmacokinetics to diagnose and treat cancer
Researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians. Teachers and advanced students of interdisciplinary nanomedicine courses
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- About the editors
- Preface
- Acknowledgment
- Chapter 1. Nanomaterials and pharmacokinetics
- Abstract
- 1.1 Introduction
- 1.2 Pharmacokinetics of nanomaterials
- 1.3 Governing parameters for pharmacokinetics of nanomaterials
- 1.4 Prime issues in the pharmacokinetics of nanomaterials
- 1.5 Challenges and future perspectives
- 1.6 Conclusions
- Acknowledgment
- Conflict of interest
- References
- Chapter 2. Nanopharmacokinetics: routes of administration and predictive models for nanopharmacokinetics
- Abstract
- 2.1 Introduction
- 2.2 Modes of administration routes of nanocarriers
- 2.3 Types of targeted drug delivery methods
- 2.4 Physiologically based pharmacokinetic modeling
- 2.5 Conclusion and future perspective
- Acknowledgement
- References
- Chapter 3. Nano-pharmacokinetics: interface of physics, chemistry and biology
- Abstract
- 3.1 Introduction
- 3.2 Physical parameters
- 3.3 Chemical parameters
- 3.4 Biological parameters
- 3.5 Conclusion
- References
- Chapter 4. Nanomaterials exposure to human
- Abstract
- 4.1 Introduction
- 4.2 Mechanism of release of engineered/manufactured nanomaterials
- 4.3 Routes of exposure of nanomaterials
- 4.4 Health effects associated with the exposure of nanomaterials
- 4.5 Discussion and future perspectives
- Acknowledgement
- References
- Chapter 5. Engineered nanomaterials and pharmacokinetics
- Abstract
- 5.1 Introduction
- 5.2 Cancer and engineered nanoparticles
- 5.3 Engineered gold nanoparticles and its pharmacokinetics studies
- 5.4 Engineered silver nanoparticles and its pharmacokinetics studies
- 5.5 Engineered quantum dots and its pharmacokinetics studies
- 5.6 Engineered carbon nanotubes and its pharmacokinetics studies
- 5.7 Engineered polymeric nanoparticle and its pharmacokinetics studies
- 5.8 Engineered titanium dioxide nanoparticles and its pharmacokinetics studies
- 5.9 Engineered graphene and its pharmacokinetics studies
- 5.10 Engineered fullerenes and its pharmacokinetics studies
- 5.11 Engineered mesoporous nanoparticles and its pharmacokinetic Studies
- 5.12 Engineered dendrimers and its pharmacokinetics studies
- 5.13 Engineered iron oxide nanoparticles and its pharmacokinetics studies
- 5.14 Conclusion
- References
- Chapter 6. Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues
- Abstract
- 6.1 Introduction
- 6.2 Safety concerns
- 6.3 Ethical implications of nanotechnology
- 6.4 Manufacturing
- 6.5 Regulation
- 6.6 Conclusions
- References
- Chapter 7. Nano-pharmacokinetics: biodistribution and toxicology
- Abstract
- 7.1 Introduction
- 7.2 Pharmacokinetic aspects of nanomedicines
- 7.3 Role of nanomaterials in pharmacokinetics of nanomedicines
- 7.4 Biodistribution and clearance aspects of nanotheranostics
- 7.5 Toxicological aspects of nanomedicines
- References
- Chapter 8. Biological systems and nanopharmacokinetics
- Abstract
- 8.1 Uptake of nanoparticles into biological system
- 8.2 Nanoparticles and extracellular matrix
- 8.3 Interaction of nanoparticles with tumor microenvironment
- 8.4 Intracellular degradation and excretion of nanoparticles
- 8.5 Conclusions
- References
- Chapter 9. Nanopharmacokinetics assessment
- Abstract
- 9.1 Introduction
- 9.2 Kinetic homogeneity
- 9.3 Concentration–response relationship
- 9.4 Drug absorption
- 9.5 Simple math equations to describe drug disposition
- 9.6 Common PK parameters assessment during absorption phase
- 9.7 Bioavailability
- 9.8 Alterations in absorption kinetics in nanodrugs
- 9.9 Biodistribution of nanoparticles
- 9.10 Metabolism of nanoparticles
- 9.11 Elimination
- 9.12 Assessment of in vitro drug release
- 9.13 Spectroscopic analytical methods for nanomedicines
- References
- Chapter 10. Clinical protocols for nanopharmacokinetics assessment
- Abstract
- 10.1 Introduction
- 10.2 Theranostics in clinical trials
- 10.3 General consideration of regulations for nanomaterials
- 10.4 Regulatory pathway for theranostics
- 10.5 Regulatory prospective on nanotheranostics
- 10.6 Guidance provided by different regulatory bodies
- 10.7 Conclusion
- Acknowledgments
- References
- Chapter 11. Nano-pharmacokinetics and cancer theranostics
- Abstract
- 11.1 Introduction
- 11.2 Pharmacokinetics of nanoformulation
- 11.3 Physiological properties of nanoformulation
- 11.4 Pharmacokinetics of nanoformulation
- 11.5 Pharmacodynamics and clinical significance
- 11.6 Conclusion
- 11.7 Future direction
- References
- Chapter 12. Nanopharmacokinetics: key role in in vivo imaging
- Abstract
- 12.1 Introduction
- 12.2 Conjugated gold nanoparticles
- 12.3 Ruthenium selenium nanohybrid
- 12.4 Conjugated silica nanoparticles
- 12.5 Metal oxide liquid crystalline nanostructures
- 12.6 Calcium phosphate nanoparticles
- 12.7 Graphene-based nanoconjugates
- 12.8 Conclusion and future scope
- Acknowledgements
- References
- Chapter 13. Pharmacokinetics/pharmacodynamics and clinical relationship
- Abstract
- 13.1 Introduction
- 13.2 Nanoscale delivery systems
- 13.3 Pharmacokinetics and pharmacodynamics
- 13.4 Impacting factors of pharmacokinetics/pharmacodynamics of nanoscale delivery systems
- 13.5 Clinical relationships
- 13.6 Conclusion
- References
- Further reading
- Chapter 14. Nano-pharmacokinetics preclinical to clinical translation
- Abstract
- 14.1 Commercial and practical feasibility
- 14.2 Current trends in the clinical translation of nanomedicines
- 14.3 Other Challenges in the clinical translation of nanomedicines
- References
- Chapter 15. Nano-pharmacokinetics: industrial transformation future outlook and conclusion
- Abstract
- 15.1 Introduction
- 15.2 Characterization of nanomedicine
- 15.3 Conclusions and future outlook
- Acknowledgment
- Conflict of Interest
- References
- Index
- Edition: 1
- Published: July 28, 2021
- Imprint: Academic Press
- No. of pages: 324
- Language: English
- Paperback ISBN: 9780323850506
- eBook ISBN: 9780323859820
NT
Nanasaheb D. Thorat
Dr. Nanasaheb Thorat is Principal Investigator funded by the Science Foundation Ireland (SFI) and Irish Research Council (IRC) Pathway Program at the University of Limerick, Ireland. He is also a Marie Curie Visiting Research Scientist at the University of Oxford, UK.
He has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Thorat has received the European Commission’s innovation Radar “Grand Prix of the Innovation Radar Prize 2020” for developing ground-breaking technology for breast cancer theranostics.NK